FR2889949A1 - Use of a cosmetic and/or dermo-cosmetic containing herbal extract base of Pyrus malus for the preparation of a cosmetic product to correct, maintain and improve the moisture level of the skin - Google Patents
Use of a cosmetic and/or dermo-cosmetic containing herbal extract base of Pyrus malus for the preparation of a cosmetic product to correct, maintain and improve the moisture level of the skin Download PDFInfo
- Publication number
- FR2889949A1 FR2889949A1 FR0508796A FR0508796A FR2889949A1 FR 2889949 A1 FR2889949 A1 FR 2889949A1 FR 0508796 A FR0508796 A FR 0508796A FR 0508796 A FR0508796 A FR 0508796A FR 2889949 A1 FR2889949 A1 FR 2889949A1
- Authority
- FR
- France
- Prior art keywords
- cosmetic
- pyrus
- dermo
- skin
- plant extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 235000011430 Malus pumila Nutrition 0.000 title abstract description 14
- 235000015103 Malus silvestris Nutrition 0.000 title abstract description 14
- 244000141359 Malus pumila Species 0.000 title abstract description 12
- 239000012676 herbal extract Substances 0.000 title abstract 4
- 102000004363 Aquaporin 3 Human genes 0.000 claims abstract description 21
- 108090000991 Aquaporin 3 Proteins 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 17
- 210000003491 skin Anatomy 0.000 claims abstract description 15
- 210000002615 epidermis Anatomy 0.000 claims description 21
- 239000000419 plant extract Substances 0.000 claims description 16
- 230000036571 hydration Effects 0.000 claims description 13
- 238000006703 hydration reaction Methods 0.000 claims description 13
- 241000220324 Pyrus Species 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229930013035 isoflavonoid derivative Natural products 0.000 claims description 3
- 150000003817 isoflavonoid derivatives Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 1
- 210000002510 keratinocyte Anatomy 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 238000004166 bioassay Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 210000002850 nasal mucosa Anatomy 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 18
- 102000010637 Aquaporins Human genes 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108010063290 Aquaporins Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OIALAIQRYISUEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]e Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO OIALAIQRYISUEV-UHFFFAOYSA-N 0.000 description 2
- 108090001004 Aquaporin 1 Proteins 0.000 description 2
- 102000004888 Aquaporin 1 Human genes 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LEVVMZZBTOYKSC-UHFFFAOYSA-N 1-amino-4-hydroxybutane-2-sulfonic acid Chemical compound NCC(S(O)(=O)=O)CCO LEVVMZZBTOYKSC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 102100029406 Aquaporin-7 Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101000771402 Homo sapiens Aquaporin-7 Proteins 0.000 description 1
- 101000771413 Homo sapiens Aquaporin-9 Proteins 0.000 description 1
- 241000138806 Impages Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 244000081841 Malus domestica Species 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229960001983 magnesium aspartate Drugs 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- CRSJYWPXKKSOCQ-CBAPHJFVSA-L magnesium;(2s)-2-aminobutanedioate;hydron;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O CRSJYWPXKKSOCQ-CBAPHJFVSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229930188627 soysaponin Natural products 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
La présente invention concerne l'utilisation d'un extrait de pyrus ma/usThe present invention relates to the use of an extract of pyrus ma / us
et en particulier d'un extrait d'huile de pépins de pyrus ma/us dans la composition et la conception de produits cosmétiques ou dermocosmétiques, et l'utilisation de ces produits dans le domaine de and in particular pyrus maize seed oil extract in the composition and design of cosmetic or dermocosmetic products, and the use of these products in the field of
l'amélioration de l'état de l'épiderme en dermocosmétique ou en cosmétique. the improvement of the condition of the epidermis in dermocosmetics or in cosmetics.
Les aquaporines sont des canaux hydriques qui sont des systèmes protéiques transmembranaires transporteurs d'eau et de petites molécules en solution telles que le glycérol et l'urée par exemple. La taille de aquaporines est d'environ 30 kDa avec six passages transmembranaires en hélice alpha (Jung et al. Molecular structure of the water channel through aquaporin CHIP dans J. Biol. Chem. 1994; vol. 269, p. 14648- 14654). Aquaporins are water channels that are transmembrane protein systems carrying water and small molecules in solution such as glycerol and urea, for example. The size of aquaporins is about 30 kDa with six alpha-helical transmembrane passages (Jung et al., Molecular structure of the water channel through aquaporin CHIP in J. Biol Chem 1994, 269, 14648-14654). .
La présence d'aquaporines de type 3 ou AQP3 dans l'épiderme humain et, plus précisément dans la membrane plasmique des kératinocytes de la peau humaine a été décrite R. SOUGRAT et al. dans un article Functional expression of AQP3 in human epidermis and keratinocyte cell cultures publié dans Molecular Biology of the Cell, Nov. 1998; vol. 9, page 499a; R. SOUGRAT et al. ont également décrit dans un article le rôle important que jouent ces AQP3 dans le transport de l'eau au sein de l'épiderme humain. The presence of aquaporins of type 3 or AQP3 in the human epidermis and, more specifically, in the plasma membrane of keratinocytes in human skin has been described R. Sougrat et al. in an article Functional expression of AQP3 in human epidermis and keratinocyte cell cultures published in Molecular Biology of the Cell, Nov. 1998; flight. 9, page 499a; R. SOUGRAT et al. have also described in an article the important role that these AQP3 play in the transport of water within the human epidermis.
L'invention concerne des extraits de fruits et en particulier de pyrus ma/us, présentant des propriétés cosmétiques intéressantes, en raison d la mise en évidence de leur action dans le domaine de l'hydratation et en particulier pour réguler et/ou améliorer la fonctionnalité des aquaporines, par exemple les aquaporines AQP1, AQP3 et AQP9. The invention relates to fruit extracts and in particular pyrus ma / us, having interesting cosmetic properties, because of the demonstration of their action in the field of hydration and in particular to regulate and / or improve the functionality of aquaporins, for example aquaporins AQP1, AQP3 and AQP9.
Ces extraits permettent, en particulier, d'améliorer la qualité des aquaporines des kératinocytes, ce qui permet d'améliorer l'hydratation de l'épiderme et d'obtenir une activité hydratante et/ou anti-vieillissement particulièrement efficace. Par ailleurs, la demanderesse a pu observer que les extraits avaient une efficacité particulière pour réguler les flux hydriques dans l'épiderme, activité qu'ils ont pu relier à une activité des extraits sur la régulation et/ou la fonctionnalité des aquaporines et en particulier sur celle des AQP3, permettant ainsi une meilleure hydratation des couches cellulaires de l'épiderme. These extracts make it possible, in particular, to improve the quality of the aquaporins of the keratinocytes, which makes it possible to improve the hydration of the epidermis and to obtain a particularly effective moisturizing and / or anti-aging activity. Moreover, the Applicant has been able to observe that the extracts were particularly effective in regulating the hydrous fluxes in the epidermis, an activity which they could relate to an activity of the extracts on the regulation and / or the functionality of the aquaporins and in particular on that of AQP3, thus allowing a better hydration of the cellular layers of the epidermis.
Ces extraits par leur activité particulière sur les kératinocytes, peuvent contribuer au renforcement du rôle de barrière hydrique de l'épiderme, en améliorant ainsi son hydratation et en jouant un rôle antivieillissement, améliorant l'aspect et la qualité de la peau, permettant ainsi d'obtenir une belle peau, une peau douce. These extracts by their particular activity on keratinocytes, can contribute to strengthening the role of water barrier of the epidermis, thus improving its hydration and playing an anti-aging role, improving the appearance and quality of the skin, thus allowing to obtain a beautiful skin, a soft skin.
L'invention concerne aussi l'utilisation d'un extrait végétal de pyrus ma/us comme actif cosmétique ou dermocosmétique, pour la préparation d'un produit cosmétique ou dermocosmétique destiné à corriger, maintenir et améliorer l'hydratation de l'épiderme. The invention also relates to the use of a plant extract of pyrus ma / us as a cosmetic or dermocosmetic active ingredient, for the preparation of a cosmetic or dermocosmetic product intended to correct, maintain and improve the hydration of the epidermis.
L'extrait végétal de pyrus ma/us contient en outre au moins un dérivé de flavonoide et/ou isoflavonoide. The plant extract of pyrus ma / us contains in addition at least one derivative of flavonoide and / or isoflavonoide.
Le pyrus ma/us est une variété connue de pommier. Pyrus ma / us is a known variety of apple tree.
Les extraits tels que définis précédemment ont une activité sur le transport de l'eau dans l'épiderme qui peut être exprimée en partie par 15 leur activité sur la régulation des aquaporines AQP3. The extracts as defined above have an activity on the transport of water in the epidermis which can be expressed in part by their activity on the regulation of aquaporin AQP3.
L'intérêt de la correction du maintien et de l'amélioration de l'hydratation de la peau est majeur. The interest of the correction of the maintenance and the improvement of the hydration of the skin is major.
Elle peut résulter des effets perturbateurs de la pollution, du stress et du froid sur l'activité cellulaire de la peau et se traduit par des symptômes du tiraillement jusqu'à l'inconfort, mais également perte d'éclat et abaissement de la fonction protectrice de la peau. It can result from the disturbing effects of pollution, stress and cold on the cellular activity of the skin and results in symptoms of tugging up to discomfort, but also loss of radiance and lowering of the protective function skin.
La perturbation de l'hydratation de la peau est également un facteur intervenant dans le vieillissement cutané. The disruption of the hydration of the skin is also a factor in cutaneous aging.
En effet, il est bien connu que, lors du vieillissement de la peau, elle devient plus fine, plus sèche donnant cet aspect fin avec écailles rencontré en particulier chez les personnes âgées. Dans la peau, il est bien connu qu'il existe un gradient d'eau de la couche basale de l'épiderme aux couches les plus superficielles du stratum corneum. Indeed, it is well known that, during the aging of the skin, it becomes thinner, drier giving this fine aspect with scales encountered especially in the elderly. In the skin, it is well known that there is a water gradient from the basal layer of the epidermis to the most superficial layers of the stratum corneum.
Les études réalisées par la demanderesse ont permis de mettre en évidence un effet de l'actif cosmétique et/ou dermocosmétique à base d'un extrait végétal de pyrus ma/us sur les aquaporines de l'épiderme par des essais sur culture d'épiderme reconstruit. The studies carried out by the applicant have made it possible to demonstrate an effect of the cosmetic and / or dermocosmetic active agent based on a plant extract of pyrus ma / us on the aquaporins of the epidermis by tests on epidermis culture. rebuilt.
Elles ont permis de mettre également en évidence un effet notable sur l'hydratation de l'épiderme et de ses couches basales donc une amélioration de la barrière hydrique de l'épiderme. They have also demonstrated a significant effect on the hydration of the epidermis and its basal layers, thus improving the water barrier of the epidermis.
L'invention concerne également une composition cosmétique ou dermocosmétique destinée à corriger, maintenir et/ou améliorer l'hydratation de l'épiderme, caractérisée en ce qu'elle contient une quantité cosmétiquement efficace d'un extrait végétal de pyrus malus. The invention also relates to a cosmetic or dermocosmetic composition intended to correct, maintain and / or improve the hydration of the epidermis, characterized in that it contains a cosmetically effective amount of a plant extract of pyrus malus.
L'extrait végétal de la composition cosmétique et/ou dermocosmétique comprend en outre au moins un dérivé flavonoïde et/ou 10 isoflavonoïde. The plant extract of the cosmetic and / or dermocosmetic composition further comprises at least one flavonoid and / or isoflavonoid derivative.
Dans un mode de réalisation, l'actif cosmétique ou dermocosmétique à base d'extrait végétal de pyrus malus est utilisé pour la préparation d'une composition cosmétique dans des proportions pondérales comprises entre 0, 0005 et 10 % par rapport au poids total de la composition. In one embodiment, the cosmetic or dermocosmetic active ingredient based on plant extract of pyrus malus is used for the preparation of a cosmetic composition in weight proportions ranging between 0.0005 and 10% relative to the total weight of the composition.
Dans un mode de réalisation, ce pourcentage pondéral est compris entre 0, 001 et 2 %. In one embodiment, this weight percentage is between 0.001 and 2%.
L'invention concerne également une composition cosmétique et/ou dermocosmétique comprenant de 0,0005 et 10 % par rapport au poids total de la composition de l'actif cosmétique et/ou dermocosmétique à base d'un extrait végétal de pyrus malus. The invention also relates to a cosmetic and / or dermocosmetic composition comprising from 0.0005 and 10% relative to the total weight of the composition of the cosmetic active ingredient and / or dermocosmetic based on a plant extract of pyrus malus.
Elle concerne également une composition cosmétique et/ou dermocosmétique comprenant entre 0,001 et 2 % dudit actif cosmétique. It also relates to a cosmetic and / or dermocosmetic composition comprising between 0.001 and 2% of said cosmetic active agent.
L'invention concerne également un procédé de traitement cosmétique caractérisé en ce que l'on applique sur la peau une quantité cosmétiquement efficace d'un actif cosmétique à base d'un extrait végétal de pyrus malus. The invention also relates to a cosmetic treatment method characterized in that a cosmetically effective amount of a cosmetic active ingredient based on a plant extract of pyrus malus is applied to the skin.
Selon un mode de réalisation, l'extrait de végétal de pyrus malus est l'extrait commercialisé sous la marque déposée EDERLINE par la société 30 IMPAG. According to one embodiment, the plant extract of pyrus malus is the extract sold under the trademark EDERLINE by the company IMPAG.
Les exemples ainsi que les tests qui suivent permettent d'illustrer l'invention et les propriétés particulières de l'actif cosmétique sur les mécanismes de l'hydratation de l'épiderme. The examples and the tests that follow illustrate the invention and the particular properties of the cosmetic active on the mechanisms of hydration of the epidermis.
TEST D'OBJECTIVATION Traitement et culture Les kératinocytes ont été précultivés en milieu d'essai SFM Ep, -EGF. Les cellules ont ensuite été traitées ou non (témoin) par les produits à l'essai et cultivées pendant 24 h à 37 C et 5 % de CO2. Chaque traitement a été réalisé en triplicata. OBJECTIVATION TEST Treatment and culture The keratinocytes were precultured in SFM Ep, EGF test medium. The cells were then treated or not (control) with the test products and cultured for 24 hours at 37 ° C and 5% CO2. Each treatment was performed in triplicate.
Les surnageants de culture ont été éliminés et les tapis cellulaires ont été rincés avec une solution de PBS (Invitrogen 14190094) puis placés dans des tubes stériles RNA-free en présence de Tri-Reagent (sigma T9424) et immédiatement congelés à -80 C. Culture supernatants were removed and the cell mats were rinsed with PBS solution (Invitrogen 14190094) and placed in sterile RNA-free tubes in the presence of Tri-Reagent (sigma T9424) and immediately frozen at -80 ° C.
RT-PCR Quantitative L'expression des marqueurs sélectionnés par le commanditaire a été évaluée par RT-Q-PCR sur les ARN messagers extraits des tapis cellulaires de chaque traitement (les triplicates ont été poolés avant l'extraction de l'ARN). Quantitative RT-PCR The expression of the markers selected by the sponsor was evaluated by RT-Q-PCR on the messenger RNA extracted from the cellular mats of each treatment (the triplicates were pooled before the extraction of the RNA).
Les couples de primers qui ont été utilisés dans cette étude permettent l'amplification des fragments spécifiques suivants: Nom du gène Abreviation GenBank n Human beta-Actin Act X00351 Aquaporin-3 AQP3 NM 004925 The pairs of primers that were used in this study allow amplification of the following specific fragments: GenBank GenBank GenBank n Human Actin Act X00351 Aquaporin-3 AQP3 NM 004925
Réverse TranscriptionReverse Transcription
Extraction des ARN totaux de chaque échantillon à l'aide de Tri-30 Reagent selon le protocole préconisé par le fournisseur. Extraction of total RNA from each sample using Tri-30 Reagent according to the protocol recommended by the supplier.
Elimination des traces d'ADN potentiellement contaminant par traitement avec le système DNA-free (Ambion). Elimination of traces of potentially contaminating DNA by treatment with the DNA-free system (Ambion).
Réalisation de la réaction de réverse-transcription de l'ARNm en présence de l'amorce oligo(dT) et de l'enzyme Superscript II (Gibco). Realization of the reverse transcription reaction of the mRNA in the presence of the primer oligo (dT) and the enzyme Superscript II (Gibco).
Quantification, par fluorescence, de dADNc synthétisé et ajustement des concentrations à 100 ng/pl. Une nouvelle quantification de chaque ARNc, après dilution finale, est réalisée avant la réaction de PCR. Fluorescence quantization of synthesized dDNAc and adjustment of concentrations to 100 ng / μl. A new quantification of each cRNA, after final dilution, is performed before the PCR reaction.
PCR Quantitative Les réactions de PCR (polymerase chain reactions) ont été réalisées par PCR quantitative avec le système Light Cycler (Roche 10 Molecular Systems Inc.) et selon les procédures recommandées par le fournisseur. Quantitative PCR PCR reactions (polymerase chain reactions) were performed by quantitative PCR with the Light Cycler system (Roche Molecular Systems Inc.) and according to the procedures recommended by the supplier.
Ce système d'analyse permet de réaliser des réactions de PCR rapides et performantes, moyennant une mise au point préalable des conditions d'analyse des différents primers. Il est formé de deux composants principaux: un thermocyc/eur: optimisé grâce à l'utilisation de capillaires en verre et à des transferts thermiques extrêmement rapides. This analysis system makes it possible to carry out fast and efficient PCR reactions, with a prior development of the analysis conditions of the different primers. It consists of two main components: a thermocyc / eur: optimized through the use of glass capillaries and extremely fast heat transfer.
un fluor/mètre: permettant de mesurer en continu l'intensité de fluorescence incorporée dans l'ADN (détection à 521 nm). a fluorine / meter: to measure continuously the fluorescence intensity incorporated in the DNA (detection at 521 nm).
Le mélange réactionnel (10 pl final) introduit dans des capillaires pour chaque échantillon est le suivant: 2.5 NI d'ADNc dilué 1/10e. The reaction mixture (10 μl final) introduced into capillaries for each sample was as follows: 2.5 NI diluted 1/10 cDNA.
amorces des différents marqueurs utilisés mélange réactionnel (Roche) contenant l'enzyme taq DNA polymérase, le marqueur SYBR Green I (fluorophore qui s'intercale dans 30 l'ADN double brin, au cours de l'étape d'élongation) et du MgCl 2. primers of the various markers used reaction mixture (Roche) containing the enzyme taq DNA polymerase, the marker SYBR Green I (fluorophore that intercalates in the double-stranded DNA, during the elongation step) and MgCl 2.
Conditions de PCR: Activation: 10 min à 95 C. PCR conditions: Activation: 10 min at 95 C.
Réactions de PCR: [10 sec à 95 C, 5 sec à 64 C et 35 sec à 35 72 C] 40 cycles. PCR reactions: [10 sec at 95 ° C., 5 sec at 64 ° C. and 35 sec at 72 ° C.] 40 cycles.
Fusion: 5 sec à 95 C puis 5 sec à 60 C puis de 60 C à 95 C (0.1 C/sec). Fusion: 5 sec at 95 C then 5 sec at 60 C then 60 C at 95 C (0.1 C / sec).
Analyse des PQ-PCR L'incorporation de fluorescence dans l'ADN amplifié est mesurée en continu au cours des cycles de PCR. Ce système permet d'obtenir des courbes de mesure de la fluorescence en fonction des cycles de PCR et d'évaluer ainsi une valeur d'expression relative pour chaque marqueur. PQ-PCR Analysis Fluorescence incorporation into the amplified DNA is measured continuously during PCR cycles. This system makes it possible to obtain fluorescence measurement curves as a function of PCR cycles and thus to evaluate a relative expression value for each marker.
Le nombre de cycles est déterminé à partir des points de sortie des courbes de fluorescence. Pour un même marqueur analysé, 15 plus un échantillon sort tard (nombre de cycle élevé), plus le nombre initial de copies de I'ARNm est faible. The number of cycles is determined from the exit points of the fluorescence curves. For the same tag analyzed, plus one sample coming out late (high cycle number), the lower the initial number of copies of the mRNA.
La valeur de RE (relative expression) est exprimée en unités arbitraires selon la formule suivante: (1 /2nombre de cycles) x 1 06 The value of RE (relative expression) is expressed in arbitrary units according to the following formula: (1 / 2number of cycles) x 1 06
RESULTATSRESULTS
Cytotoxicité sur kératinocytes humains normaux (NHDF) Les résultats des tests de viabilité au MTT et l'observation des tapis cellulaires ont conduit à sélectionner, en accord avec le commanditaire, une concentration non-cytotoxique à tester pour chaque produit à l'essai. Cytotoxicity on normal human keratinocytes (NHDF) The results of the MTT viability tests and the observation of the cell mats led to the selection, in agreement with the sponsor, of a non-cytotoxic concentration to be tested for each product under test.
Effets sur l'expression du marqueur Aquaporine 3 (AQP3) Afin de confirmer les effets observés, deux PCRs indépendantes ont été réalisées dans cette étude. Effects on the expression of the Aquaporin 3 marker (AQP3) In order to confirm the observed effects, two independent PCRs were carried out in this study.
Dans les conditions expérimentales de ces essais, le sorbitol testé à 20 mg/ml (référence positive) a stimulé l'expression relative du marqueur Aquaporine 3 dans les cultures de kératinocytes humains (192 % et 185 % du témoin). Under the experimental conditions of these tests, the sorbitol tested at 20 mg / ml (positive reference) stimulated the relative expression of the Aquaporin 3 marker in human keratinocyte cultures (192% and 185% of the control).
L'acide rétinoïque testé à 10-6 M n'a pas montré d'effet significatif sur l'expression d'AQP3. Ce composé, connu pour ses effets inhibiteurs de la différenciation, aurait pu modifier le taux d'expression de l'AQP3. Il a été montré qu'il modulait cette expression dans les modèles de culture de kératinocytes d'épithélium nasal, mais seulement lorsque ceux-ci sont cultivés sur filtre, à l'interface air-eau. Par ailleurs, des essais de R&D réalisés dans notre laboratoire ont montré que les effets de l'acide rétinoïque sur la différenciation des kératinocytes de l'épiderme sont faibles dans les cultures en monocouche alors qu'ils sont réellement notables dans le modèle d'épiderme reconstruit. Ainsi il n'est pas surprenant que l'acide rétinoïque n'ait pas montré d'effet dans cet essai. Retinoic acid tested at 10-6 M showed no significant effect on AQP3 expression. This compound, known for its inhibitory effects of differentiation, could have changed the level of expression of AQP3. It has been shown to modulate this expression in nasal epithelial keratinocyte culture models, but only when cultured on a filter at the air-water interface. Moreover, R & D tests carried out in our laboratory have shown that the effects of retinoic acid on the differentiation of epidermal keratinocytes are weak in monolayer cultures whereas they are really noticeable in the epidermis model. rebuilt. Thus it is not surprising that retinoic acid did not show any effect in this test.
AQP3/Actine - PCRn 1 Traitement Concentration Cycles Cycles RE*Act RE*AQP3 % témoin Act AQP3 (UA) (UA) Témoin 1 - 16.19 18.71 13.612 2.373 100 16.14 18.66 Témoin 2 - 16.05 18.60 14.842 2.400 93 16.03 18.74 Acide 10-6 M 16.22 18.43 13.474 2.923 124 rétinoique 16.14 18.34 Extrait 0.01 % 16.31 18.19 12.614 3.254 148 de Soja 16.24 18.27 Extrait 0.1 % 16.46 18. 16 11.093 3.322 172 de pomme 16.46 18.24 Sorbitol 20 mg/mi 16.19 17.86 13. 148 4.402 192 16.24 17.73 RE* = Expression relative, exprimée en unités arbitraires (UA) n=1; première série de PCR AQP3/Actine PCRn 2 Traitement Concentration Cycles Cycles RE*Act RE*AQP3 % témoin Act AQP3 (UA) (UA) Témoin 1 - 17.21 19.11 6.689 1.731 100 17.17 19.17 Témoin 2 -17. 00 19.26 7.301 1686 89 17.13 19.10 Acide 10-6 M 17.18 18.93 6.853 1.995 112 rétinoique 17.13 18.94 Extrait 0.01% 17.47 18.83 5.586 2.168 150 de Soja 17.43 18.80 Extrait 0.1% 16.97 18.42 7.844 2.822 139 de pomme 16.95 18.45 Sorbitol 20 mg/mi 17.32 18.29 6.331 3.026 185 17.22 18.38 RE* = Expression relative, exprimée en unités arbitraires (UA) n=2; deuxième série de PCR Par ailleurs, l'extrait de pyrus malus selon la présente invention est avantageusement utilisé dans les compositions de l'invention en combinaison avec tout autre principe actif connu de l'homme de l'art, en particulier avec tout autre principe actif choisi dans le groupe constitué des vitamines et de /ou de leurs esters, les extraits de racines de plantes riches en aquaporines végétales, I'aspartate de magnésium, le chlorure de manganèse, l'acide hyaluronique, le gluconate de calcium. AQP3 / Actin - PCRn 1 Treatment Concentration Cycles Cycles RE * Act RE * AQP3% control Act AQP3 (UA) (AU) Control 1 - 16.19 18.71 13.612 2.373 100 16.14 18.66 Control 2 - 16.05 18.60 14.842 2.400 93 16.03 18.74 Acid 10-6 M 16.22 18.43 13.474 2.923 124 retinoic 16.14 18.34 Extract 0.01% 16.31 18.19 12.614 3.254 148 Soy 16.24 18.27 Extract 0.1% 16.46 18. 16 11.093 3.322 172 of apple 16.46 18.24 Sorbitol 20 mg / mi 16.19 17.86 13. 148 4.402 192 16.24 17.73 RE * = Relative expression, expressed in arbitrary units (UA) n = 1; first series of PCR AQP3 / Actin PCRn 2 Treatment Concentration Cycles Cycles RE * Act RE * AQP3% control Act AQP3 (UA) (UA) Control 1 - 17.21 19.11 6.689 1.731 100 17.17 19.17 Control 2 -17. 00 19.26 7.301 1686 89 17.13 19.10 Acid 10-6 M 17.18 18.93 6.853 1.995 112 Retinoic 17.13 18.94 Extract 0.01% 17.47 18.83 5.586 2.168 150 Soy 17.43 18.80 Extract 0.1% 16.97 18.42 7.844 2.822 139 Apple 16.95 18.45 Sorbitol 20 mg / mi 17.32 18.29 6.331 3.026 185 17.22 18.38 RE * = Relative expression, expressed in arbitrary units (UA) n = 2; second series of PCR Furthermore, the pyrus malus extract according to the present invention is advantageously used in the compositions of the invention in combination with any other active principle known to those skilled in the art, in particular with any other principle active agent selected from the group consisting of vitamins and / or their esters, extracts of plant roots rich in vegetable aquaporins, magnesium aspartate, manganese chloride, hyaluronic acid, calcium gluconate.
Comme démontré par les tests, des extraits de soja ont également une activité interessante sur la régulation et/ou la fonctionnalité des aquaporines et peuvent être utilisés à titre d'ingrédients cosmétiques seuls ou en mélange pour la préparation de compositions cosmétiques destinées à corriger, maintenir et améliorer l'hydratation de l'épiderme. As demonstrated by the tests, soy extracts also have an interesting activity on the regulation and / or the functionality of aquaporins and can be used as cosmetic ingredients alone or as a mixture for the preparation of cosmetic compositions intended to correct, maintain and improve the hydration of the epidermis.
D'une façon générale, les compositions cosmétiques de l'invention contiennent des excipients ou supports cosmétiquement acceptables pour une application topique sur la peau. Des exemples de tels excipients ou supports cosmétiquement acceptables sont bien connus de l'homme de l'art. In general, the cosmetic compositions of the invention contain cosmetically acceptable excipients or carriers for topical application to the skin. Examples of such cosmetically acceptable excipients or carriers are well known to those skilled in the art.
Dans un mode de réalisaton, la composition cosmétique et/ou dermocosmétique selon l'invention contient en outre au moins une substance choisie dans le groupe consituté des acides aminés, l'acide hyaluronique, la glycérine, le sorbitol, le xylitol, la Tri-Methyle glycine. In one embodiment, the cosmetic and / or dermocosmetic composition according to the invention also contains at least one substance chosen from the group consisting of amino acids, hyaluronic acid, glycerine, sorbitol, xylitol Methyl glycine.
Les compositions de l'invention peuvent être formulées sous toute forme cosmétiquement acceptable, en particulier sous forme de crème, de gel, de lotion. Les exemples qui suivent ne sont nullement limitatifs. 7 % Exemple 1: Emulsion H/E - Alcool cétylique - Stéarate de glycéryle 2,5 % Stéarate de PEG-50 2,5 % - Myristate d'isopropyle 3 % - Extrait pyrus malus(Ederline ) 0.25 % - Acétate de vitamine E 1.00 % - Palmitate de vitamine A 0.10 % - Ascorbyle phosphate de magnésium 2.00 % - Acide piperazine-N,N'-bis[2-éthanesulfonique] 10 % conservateurs 0,3 % - Soude qsp pH =7 0.2 - Eau qsp 100 % Exemple 2: Emulsion H/E 7 % - Alcool cétylique Stéarate de glycéryle 2,5 % Stéarate de PEG-50 2,5 % - Huile de vaseline 6,2 % - Myristate d'isopropyle 3 % - Ederline 0,40 % - Chlorure de manganèse 1,00% - D-xylose 1,00 % - Acide N,N'-bis[2-Hydroxyéthyl]-2aminoéthanesulfonique 7,1% - conservateurs 0,3 % - Soude qsp pH=7 0.2 Eau qsp 100 Exemple 3: Gel hydratant - Brij 721 2,4 % - Extrait huileux de pyrus malus( Ederline ) 0,40 % - Aspartame de magnésium 1,00 % - Saponines de soja 0,50 - Volpo S72 2,6 % -Prostéaryl-15 8,0 - Cire d'abeille 0,5 % Abil ZP2434 3,0 % - Propylène glycol 3,0 - Carbopol 941 0,25 Triéthanolamine 0,25 % - Extrait d'/mperata Cy/indrica L. 3,0 % - Eau, conservateurs qsp 100 Exemple 4: Lotion hydratante et tonifiante Ederline 0,01 % Caféine 0,10 Twen 20 2.00 Cérimide BP 0.15 Eau & parfums qsp. 100 g The compositions of the invention may be formulated in any cosmetically acceptable form, in particular in the form of cream, gel or lotion. The following examples are in no way limiting. 7% Example 1: O / W Emulsion - Cetyl Alcohol - Glyceryl Stearate 2.5% PEG-50 Stearate 2.5% - Isopropyl Myristate 3% - Pyrus Malus Extract (Ederline) 0.25% - Vitamin E Acetate 1.00% - Vitamin A Palmitate 0.10% - Ascorbyl Magnesium Phosphate 2.00% - Piperazine-N, N'-bis [2-ethanesulfonic acid] 10% preservatives 0.3% - Soda qs pH = 7 0.2 - Water qs 100% Example 2: O / W Emulsion 7% - Cetyl Alcohol Glyceryl Stearate 2.5% PEG-50 Stearate 2.5% - Vaseline Oil 6.2% - Isopropyl Myristate 3% - Ederline 0.40% - Manganese chloride 1.00% - D-xylose 1.00% - N, N'-bis [2-Hydroxyethyl] -2-aminoethanesulfonic acid 7.1% - preservatives 0.3% - Soda qs pH = 7 0.2 Water qs 100 Example 3 Moisturizing Gel Brij 721 2.4% Oily Extract Pyrus Malus (Ederline) 0.40% Magnesium Aspartame 1.00% Soy Saponins 0.50 Volpo S72 2.6% Prostearyl 8.0 8.0 - Beeswax 0.5% Abil ZP2434 3.0% - Propylene Glycol 3.0 - Carbopol 941 0.25 Triethanolamine 0.25% - Cy / indrica L. / mperata extract 3.0% - Water, preservatives qs 100 Example 4: Moisturizing and toning lotion Ederline 0.01% Caffeine 0.10 Twen 20 2.00 Cérimide BP 0.15 Water & fragrances qsp. 100 g
Claims (11)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508796A FR2889949B1 (en) | 2005-08-26 | 2005-08-26 | USE OF A COSMETIC AND / OR DERMOCOSMETIC ACTIVE BASE WITH PLANT PYRUS MALUS EXTRACT |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508796A FR2889949B1 (en) | 2005-08-26 | 2005-08-26 | USE OF A COSMETIC AND / OR DERMOCOSMETIC ACTIVE BASE WITH PLANT PYRUS MALUS EXTRACT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2889949A1 true FR2889949A1 (en) | 2007-03-02 |
| FR2889949B1 FR2889949B1 (en) | 2014-01-10 |
Family
ID=36717045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0508796A Active FR2889949B1 (en) | 2005-08-26 | 2005-08-26 | USE OF A COSMETIC AND / OR DERMOCOSMETIC ACTIVE BASE WITH PLANT PYRUS MALUS EXTRACT |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2889949B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2925332A1 (en) * | 2007-12-21 | 2009-06-26 | Vincience Sa | USE OF A SPOTLIGHT HYDROLYZATE AS AN ACTIVATOR ACTIVE INGREDIENT OF AQUAPORIN SYNTHESIS |
| WO2012130771A1 (en) | 2011-03-25 | 2012-10-04 | Lipotec S.A. | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5344639A (en) * | 1976-10-04 | 1978-04-21 | Kouichi Ogawa | Cosmetics |
| JPH1171294A (en) * | 1997-08-29 | 1999-03-16 | Pias Arise Kk | Collagenase inhibitor |
| JP2000344655A (en) * | 1999-06-01 | 2000-12-12 | Fancl Corp | Skin cosmetic |
| JP2002363025A (en) * | 2001-06-01 | 2002-12-18 | Nippon Zettoc Co Ltd | Skin care preparation and method for producing the same |
| JP2003160433A (en) * | 2001-11-27 | 2003-06-03 | Shiseido Co Ltd | Anti-aging skin preparation for external use |
| WO2003053394A2 (en) * | 2001-12-21 | 2003-07-03 | Henkel Kommanditgesellschaft Auf Aktien | Use of apple core extracts in cosmetic or pharmaceutical co mpositions |
| JP2004131500A (en) * | 2002-09-19 | 2004-04-30 | Fancl Corp | Skin aging inhibitor or improver |
| JP3529811B2 (en) * | 1993-06-30 | 2004-05-24 | 三省製薬株式会社 | External preparation for skin |
| EP1428520A2 (en) * | 2002-12-10 | 2004-06-16 | Henkel Kommanditgesellschaft auf Aktien | Lipase inhibitors in deodorants and antiperspirants |
| WO2006018198A1 (en) * | 2004-08-13 | 2006-02-23 | Henkel Kommanditgesellschaft Auf Aktien | Cosmetic and dermatological compositions comprising (2-hydroxyethyl)urea |
| EP1640041A2 (en) * | 2004-09-24 | 2006-03-29 | Henkel Kommanditgesellschaft auf Aktien | Cosmetic and dermatological composition for the treatment of aging or photodamaged skin |
| EP1671673A1 (en) * | 2004-12-20 | 2006-06-21 | Henkel Kommanditgesellschaft auf Aktien | Pigments containing water-in-siliconoil-emulsion for improving the appearance of the skin |
-
2005
- 2005-08-26 FR FR0508796A patent/FR2889949B1/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5344639A (en) * | 1976-10-04 | 1978-04-21 | Kouichi Ogawa | Cosmetics |
| JP3529811B2 (en) * | 1993-06-30 | 2004-05-24 | 三省製薬株式会社 | External preparation for skin |
| JPH1171294A (en) * | 1997-08-29 | 1999-03-16 | Pias Arise Kk | Collagenase inhibitor |
| JP2000344655A (en) * | 1999-06-01 | 2000-12-12 | Fancl Corp | Skin cosmetic |
| JP2002363025A (en) * | 2001-06-01 | 2002-12-18 | Nippon Zettoc Co Ltd | Skin care preparation and method for producing the same |
| JP2003160433A (en) * | 2001-11-27 | 2003-06-03 | Shiseido Co Ltd | Anti-aging skin preparation for external use |
| WO2003053394A2 (en) * | 2001-12-21 | 2003-07-03 | Henkel Kommanditgesellschaft Auf Aktien | Use of apple core extracts in cosmetic or pharmaceutical co mpositions |
| JP2004131500A (en) * | 2002-09-19 | 2004-04-30 | Fancl Corp | Skin aging inhibitor or improver |
| EP1428520A2 (en) * | 2002-12-10 | 2004-06-16 | Henkel Kommanditgesellschaft auf Aktien | Lipase inhibitors in deodorants and antiperspirants |
| WO2006018198A1 (en) * | 2004-08-13 | 2006-02-23 | Henkel Kommanditgesellschaft Auf Aktien | Cosmetic and dermatological compositions comprising (2-hydroxyethyl)urea |
| EP1640041A2 (en) * | 2004-09-24 | 2006-03-29 | Henkel Kommanditgesellschaft auf Aktien | Cosmetic and dermatological composition for the treatment of aging or photodamaged skin |
| EP1671673A1 (en) * | 2004-12-20 | 2006-06-21 | Henkel Kommanditgesellschaft auf Aktien | Pigments containing water-in-siliconoil-emulsion for improving the appearance of the skin |
Non-Patent Citations (12)
| Title |
|---|
| ANONYMOUS: "Guinot Time Release Youth Boost Eyes", INTERNET ARTICLE, 15 February 2005 (2005-02-15), XP002393890, Retrieved from the Internet <URL:http://web.archive.org/web/20050215074047/http://skin-one.com/gutyreyloboey.html> [retrieved on 20060807] * |
| DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 31 August 1999 (1999-08-31), CHIGARINA K M ET AL: "Night nutrient cream", XP002250830, retrieved from STN Database accession no. 2001:875796 * |
| DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; 12 December 2000 (2000-12-12), XP002396581 * |
| DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; 30 April 2004 (2004-04-30), XP002396580 * |
| DATABASE WPI Section Ch Week 197822, Derwent World Patents Index; Class D21, AN 1978-39536A, XP002250831, "Cosmetics contg. apple extract - comprising apple alcohol and its fatty acid ester(s)" * |
| DATABASE WPI Section Ch Week 199921, Derwent World Patents Index; Class B04, AN 1999-248450, XP002250832, "New collagenase inhibitor comprising apple and/or grape seed extracts useful for preventing depletion of skin collagen" * |
| DATABASE WPI Section Ch Week 200338, Derwent World Patents Index; Class B05, AN 2003-397395, XP002396586 * |
| DATABASE WPI Section Ch Week 200377, Derwent World Patents Index; Class B04, AN 2003-818769, XP002396588 * |
| DATABASE WPI Section Ch Week 200433, Derwent World Patents Index; Class B02, AN 2004-352908 * |
| DATABASE WPI Section Ch Week 200434, Derwent World Patents Index; Class A96, AN 1995-093751, XP002396587 * |
| IMPAG: "Pinboard", IMPAG NEWS, October 2002 (2002-10-01), XP002393892, Retrieved from the Internet <URL:http://www.impag.de/german/kosmetik/z12pin.htm> [retrieved on 20060807] * |
| IMPAG: "The Power of the Apple", IMPAG NEWS, no. 8, January 2001 (2001-01-01), XP002393891, Retrieved from the Internet <URL:http://www.impag.de/english/kosmetik/z8apfel.htm> [retrieved on 20060807] * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2925332A1 (en) * | 2007-12-21 | 2009-06-26 | Vincience Sa | USE OF A SPOTLIGHT HYDROLYZATE AS AN ACTIVATOR ACTIVE INGREDIENT OF AQUAPORIN SYNTHESIS |
| WO2012130771A1 (en) | 2011-03-25 | 2012-10-04 | Lipotec S.A. | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
| US9067967B2 (en) | 2011-03-25 | 2015-06-30 | Lipotec, S.A. | Peptides useful in the treatment and care of the skin and mucous membranes and their use in cosmetic or pharmaceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2889949B1 (en) | 2014-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2953611B1 (en) | Use of a composition comprising avocado perseose in the protection of epidermal stem cells | |
| JP6846422B2 (en) | PALMARIA PALMATA and jasmine synergistic extracts, compositions containing them and their use | |
| EP3280497B1 (en) | Hydroalcoholic extract ofschinus molle, cosmetic compositions comprising the same and cosmetic uses thereof | |
| EP1928447A2 (en) | Vanilla planifolia extract, method for obtaining same, and cosmetic or dermatological composition containing same | |
| FR2977491A1 (en) | COSMETIC COMPOSITION COMPRISING A MIXTURE OF HONEY | |
| WO2007107856A1 (en) | Magnolia champaca oil, its process of preparation and compositions comprising it | |
| FR3043329A1 (en) | COSMETIC OR DERMATOLOGICAL COMPOSITION AND USE THEREOF | |
| EP2763652B1 (en) | Use of glucans obtained from prunus persica as an anti-aging cosmetic agent | |
| KR20210107724A (en) | rosewood extract | |
| WO2019069007A1 (en) | Process for using a let-7b inhibitor in cosmetics and/or nutraceuticals | |
| FR2889949A1 (en) | Use of a cosmetic and/or dermo-cosmetic containing herbal extract base of Pyrus malus for the preparation of a cosmetic product to correct, maintain and improve the moisture level of the skin | |
| FR3031458B1 (en) | SALAD EXTRACTS, COMPOSITIONS AND USES | |
| FR2971711A1 (en) | Use of extract of Einkorn wheat (Triticum monococcum), as active agent for activating synthesis of extracellular matrix protein of skin, in cosmetic composition comprising medium for fighting against the appearance of signs of skin aging | |
| FR3076461A1 (en) | Cosmetic composition of active prevention signs of age. | |
| FR3018448A1 (en) | ACTIVE PRINCIPLE OBTAINED FROM ALGAE HYPNEA MUSCIFORMIS AND COSMETIC USES | |
| EP1837392A1 (en) | Oil of magnolia champaca, method for its preparation and compositions containing same | |
| FR3072289A1 (en) | COSMETIC COMPOSITION FOR ACTIVE PREVENTION OF AGE SIGNS | |
| KR102696212B1 (en) | Synergistic extracts of Palmaria palmata and jasmine and compositions containing the same and uses thereof | |
| FR3018685B1 (en) | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF SALICARIA | |
| WO2022208005A1 (en) | Cosmetic composition comprising at least one birch extract and at least one beech bud extract | |
| EP3763355A1 (en) | Composition comprising passion flower seed polyphenols, avocado peptides and an extract of witch hazel and use for treating and/or preventing stretch marks | |
| EP4135735A1 (en) | Active principle comprising a peel extract of immature punica granatum fruit and uses for preventing and/or combatting acne | |
| FR3097127A1 (en) | Method of using a Let-7b inhibitor in cosmetics and / or nutraceuticals | |
| FR3004937A1 (en) | USE OF AN ESSENTIAL OIL OF ORIGANUM MAJORANA AS AGENT FOR TREATING AND / OR PREVENTING FAT SKINS AND / OR ASSOCIATED SKIN AHEET DEFECTS | |
| WO2009002208A1 (en) | Microbiotic collagenase-based cosmetic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 12 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 14 |
|
| PLFP | Fee payment |
Year of fee payment: 15 |
|
| PLFP | Fee payment |
Year of fee payment: 16 |
|
| PLFP | Fee payment |
Year of fee payment: 17 |
|
| PLFP | Fee payment |
Year of fee payment: 18 |
|
| PLFP | Fee payment |
Year of fee payment: 19 |
|
| AU | Other action affecting the ownership or exploitation of an industrial property right |
Effective date: 20231016 |
|
| CL | Concession to grant licences |
Name of requester: NAOS, FR Effective date: 20231016 Name of requester: NAOS INSTITUTE OF LIFE SCIENCE, FR Effective date: 20231016 |